Nektar Therapeutics Files 8-K
Ticker: NKTR · Form: 8-K · Filed: Nov 7, 2024 · CIK: 906709
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: NKTR
TL;DR
Nektar filed an 8-K on Nov 7th, expect financial updates soon.
AI Summary
Nektar Therapeutics filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational updates within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a routine update on Nektar Therapeutics' financial status and operational results, providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- November 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco, California 94158 (address) — Principal Executive Offices
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing is related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures within this excerpt.
When was the earliest event reported in this filing?
The earliest event reported is dated November 7, 2024.
What is Nektar Therapeutics' state of incorporation?
Nektar Therapeutics is incorporated in Delaware.
Where are Nektar Therapeutics' principal executive offices located?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the SEC file number for Nektar Therapeutics?
The SEC file number for Nektar Therapeutics is 0-24006.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-07 16:31:07
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0220296-8k_nektar.htm (8-K) — 25KB
- ea022029601ex99-1_nektar.htm (EX-99.1) — 87KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-095423.txt ( ) — 295KB
- nktr-20241107.xsd (EX-101.SCH) — 3KB
- nktr-20241107_lab.xml (EX-101.LAB) — 33KB
- nktr-20241107_pre.xml (EX-101.PRE) — 22KB
- ea0220296-8k_nektar_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On November 7, 2024, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended September 30, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports Third Quarter 2024 Financial Results." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: November 7, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2